DNA/RNA Extraction Kit Market to Reach US$ 6.9 Billion by 2032 at 13.2% CAGR; North America Holds 40% Share | Key Players Thermo Fisher, QIAGEN, Bio-Rad

The DNA/RNA Extraction Kit Market reached US$ 2.6 billion in 2024 and is expected to reach US$ 6.9 billion by 2032, growing at a CAGR of 13.2% during the forecast period 2025-2032. The market is expanding steadily as molecular diagnostics, genomics research, and precision medicine gain wider adoption across clinical, academic, and biopharmaceutical settings.

Growth is driven by increasing demand for rapid and accurate nucleic acid extraction in applications such as infectious disease testing, oncology research, genetic screening, and next-generation sequencing. Technological advancements enabling automation, high-throughput processing, and improved extraction efficiency are further supporting market growth. Rising investments in life sciences research and the continued expansion of diagnostic and biopharmaceutical infrastructure are reinforcing sustained market development.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/dna-and-rna-extraction-kit-market?sai-v

DNA/RNA Extraction Kit is a laboratory product designed to isolate and purify DNA or RNA from biological samples for use in molecular biology, diagnostics, and research applications.

Key Developments
✅ January 2026: In the United States, biotechnology and diagnostics companies increased adoption of automated and high-throughput DNA/RNA extraction kits to support molecular diagnostics, clinical research, and large-scale genomic and transcriptomic studies.

✅ January 2026: In Japan, life sciences companies advanced development of extraction kits optimized for high-purity nucleic acid recovery from complex samples, supporting applications in infectious disease testing, oncology research, and precision medicine.

✅ January 2026: In Asia-Pacific, demand for DNA/RNA extraction kits rose across academic research, diagnostic laboratories, and biopharma manufacturing as genomic testing, vaccine research, and molecular surveillance expanded.

✅ December 2025: In the United States, laboratories increased use of magnetic bead-based and automation-compatible extraction kits to improve workflow efficiency, reproducibility, and turnaround time in high-volume testing environments.

✅ December 2025: In Japan, manufacturers collaborated with clinical labs and instrument providers to enhance kit compatibility with automated extraction platforms and downstream PCR and sequencing workflows.

✅ December 2025: In Europe, regulatory emphasis on quality assurance and standardization supported adoption of CE-compliant DNA/RNA extraction kits across clinical diagnostics, research, and pharmaceutical applications.

Mergers & Acquisitions
✅ January 2026: In the United States, a leading life sciences tools company acquired a nucleic acid extraction kit manufacturer to expand its molecular diagnostics and sample preparation portfolio.

✅ December 2025: In the United States, a diagnostics firm completed the acquisition of a specialized DNA/RNA extraction technology provider to strengthen integrated sample-to-result solutions.

✅ December 2025: In Japan, a biotechnology company increased its investment in a nucleic acid extraction kit developer focusing on automation-ready and high-sensitivity technologies.

✅ August 2025: In Europe, a global laboratory consumables company acquired a regional DNA/RNA extraction kit producer to expand manufacturing capacity and meet growing demand from clinical and research laboratories.

Key Players
Thermo Fisher Scientific Inc. | Primerdesign | QIAGEN N.V. | RevoluGen | Bioneer Corp | BioFire Defense | General Biosystems | Akonni Biosystems | Promega Corporation | Bio-Rad Laboratories | Others

Key Highlights
Thermo Fisher Scientific Inc. holds 24.9% share, driven by its comprehensive molecular diagnostics portfolio, global distribution network, and strong adoption across clinical, research, and applied testing laboratories.

QIAGEN N.V. holds 18.6% share, supported by its leadership in sample preparation, molecular testing solutions, and strong presence in infectious disease and life science research markets.

Bio-Rad Laboratories holds 14.2% share, leveraging advanced PCR, real-time qPCR, and digital PCR technologies with strong penetration in diagnostics and research applications.

Promega Corporation holds 11.1% share, driven by its enzyme systems, nucleic acid analysis tools, and widespread use in molecular biology and diagnostics workflows.

Primerdesign holds 8.7% share, supported by specialized PCR assay design, infectious disease testing solutions, and rapid-response diagnostic capabilities.

BioFire Defense holds 7.3% share, leveraging syndromic testing platforms and rapid molecular diagnostics for biodefense and clinical applications.

Bioneer Corp holds 6.1% share, driven by integrated molecular biology products, PCR reagents, and growing adoption in academic and diagnostic laboratories.

RevoluGen holds 4.3% share, focused on novel nucleic acid extraction technologies and streamlined molecular testing workflows.

Akonni Biosystems holds 2.8% share, supported by multiplex PCR platforms and point-of-need molecular diagnostic solutions.

General Biosystems holds 1.5% share, contributing through niche molecular biology tools and customized diagnostic solutions.

Others account for 0.5% share, comprising emerging biotechnology firms and regional players offering specialized molecular diagnostics and assay development solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=dna-and-rna-extraction-kit-market?sai-v

Market Drivers
- Rising demand for molecular diagnostics, genetic testing, and infectious disease detection across clinical and research laboratories.

- Growing use of PCR, next-generation sequencing (NGS), and gene expression analysis requiring high-quality DNA and RNA extraction.

- Expansion of genomics, proteomics, and personalized medicine research worldwide.

- Increasing prevalence of chronic diseases and cancer driving demand for advanced molecular testing solutions.

- Rising investments in life sciences research, biotechnology, and diagnostic infrastructure.

Industry Developments
- Launch of automated and high-throughput DNA/RNA extraction kits to support large-scale testing and laboratory efficiency.

- Integration of magnetic bead-based and column-free extraction technologies for improved yield and purity.

- Strategic collaborations between kit manufacturers, diagnostic companies, and research institutions.

- Development of specialized kits for viral RNA, circulating tumor DNA (ctDNA), and single-cell applications.

- Expansion of point-of-care and rapid molecular testing solutions incorporating simplified extraction workflows.

Regional Insights
North America - 40% share: "Driven by advanced research infrastructure, high adoption of molecular diagnostics, and strong funding for genomics and biotechnology."

Europe - 28% share: "Supported by increasing genomic research, well-established clinical laboratories, and strong regulatory standards."

Asia Pacific - 25% share: "Fueled by expanding healthcare infrastructure, growing biotechnology sector, and rising demand for diagnostic testing."

Latin America - 5% share: "Driven by improving laboratory capabilities, increasing infectious disease testing, and gradual adoption of molecular diagnostics."

Middle East & Africa - 2% share: "Supported by expanding diagnostic services, public health initiatives, and growing awareness of molecular testing technologies."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/dna-and-rna-extraction-kit-market?sai-v

Key Segments

By Type
Cell-free DNA represents a major segment, driven by growing use in non-invasive diagnostics, oncology testing, and prenatal screening. Sequence-specific DNA holds a significant share, supported by targeted assays and molecular diagnostic applications. Total nucleic acid, including RNA and DNA, is widely used, driven by comprehensive genomic and transcriptomic analysis needs. Sequence-specific RNA is gaining traction, supported by gene expression studies and infectious disease testing. Purified RNAs account for a notable segment, driven by research and therapeutic development applications. Viral RNA is an important segment, supported by molecular testing for viral infections and outbreak monitoring. Other types include specialty nucleic acids used in advanced research and diagnostic workflows.

By End-User
Hospitals dominate adoption, driven by increasing demand for molecular diagnostics and personalized medicine. Laboratories represent a significant segment, supported by high-throughput testing, research activities, and clinical trials. Other end-users include academic institutions, biotechnology companies, and research centers.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.